Suzuki Gen, Kunikane Eriko, Shigemi Wakasa, Shinno Keisuke, Kozai Seiko, Kurata Masaaki, Kawamura Akio
Research & Development Division, Senju Pharmaceutical Co., Ltd ., Osaka, Japan.
Curr Eye Res. 2021 Mar;46(3):380-386. doi: 10.1080/02713683.2020.1800046. Epub 2020 Aug 12.
The aim of this study was to compare the ocular and systemic absorption of brimonidine (BMD) and brinzolamide (BZM) in rabbits after the topical administration of a fixed-combination ophthalmic suspension of 0.1% BMD tartrate and 1% BZM (FCBB) with that after the administration of the respective single-drug formulations.
Ocular and systemic drug absorption was estimated by determining BMD and BZM concentrations in the aqueous humor, retina/choroid, vitreous body, and blood/plasma by liquid chromatography/tandem mass spectrometry after the administration of FCBB, 0.1% BMD tartrate ophthalmic solution (0.1% BMD), or 1% BZM ophthalmic suspension (1% BZM) to rabbits.
In concomitant administration, instilling 0.1% BMD and 1% BZM successively without interval lowered aqueous humor concentrations of both drugs compared to those observed with a 5-min interval. After FCBB administration, BMD and BZM concentrations in the aqueous humor were comparable with those observed after the administration of 0.1% BMD and 1% BZM, whereas BMD concentrations in posterior ocular tissues were equal to or higher than those observed after 0.1% BMD. Plasma BMD concentrations following the administration of FCBB were 0.8-fold lower than those after 0.1% BMD; no remarkable differences were observed in blood BZM concentrations for both formulations.
FCBB achieved drug distribution in the aqueous humor and systemic exposure that were comparable to those for the single-drug formulations. The viscosity of FCBB may increase BMD distribution in the retina/choroid. The administration interval affects ocular drug absorption with the concomitant administration of 0.1% BMD and 1% BZM, which can be overcome by using the fixed-combination of both drugs.
本研究旨在比较0.1%酒石酸溴莫尼定(BMD)和1%布林佐胺(BZM)的固定组合眼用混悬液(FCBB)与各自单药制剂局部给药后,家兔眼内及全身对BMD和BZM的吸收情况。
通过液相色谱/串联质谱法测定家兔分别给予FCBB、0.1%酒石酸溴莫尼定眼用溶液(0.1%BMD)或1%布林佐胺眼用混悬液(1%BZM)后房水、视网膜/脉络膜、玻璃体及血液/血浆中BMD和BZM的浓度,以评估眼内及全身药物吸收情况。
联合给药时,0.1%BMD和1%BZM连续无间隔滴注与间隔5分钟滴注相比,两种药物的房水浓度均降低。给予FCBB后,房水中BMD和BZM的浓度与给予0.1%BMD和1%BZM后观察到的浓度相当,而后部眼组织中BMD的浓度等于或高于给予0.1%BMD后观察到的浓度。给予FCBB后血浆中BMD的浓度比给予0.1%BMD后低0.8倍;两种制剂的血液中BZM浓度未观察到显著差异。
FCBB在房水中的药物分布和全身暴露与单药制剂相当。FCBB的粘度可能会增加BMD在视网膜/脉络膜中的分布。给药间隔会影响0.1%BMD和1%BZM联合给药时的眼内药物吸收,而使用两种药物的固定组合可以克服这一问题。